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See Articles, pages 526–532 and pages 533–540Currently available antiviral treatment for chronic hepatitis B
(CHB) infection can be divided into two classes of therapeutic
agents: pegylated interferon alpha (PegIFN) and nucleos(t)ide
analogues (NAs). The advantages of PegIFN include a ﬁnite course
of treatment, the absence of drug resistance, and an opportunity
to obtain a durable post-treatment response to therapy. However,
PegIFN carries numerous side effects and the treatment is suc-
cessful in only 30–40% of patients. The advantages of NAs are
excellent tolerance and potent antiviral activity associated with
high rates of on-treatment response to therapy. New oral NAs
such as entecavir and tenofovir effectively suppress hepatitis B
virus (HBV) with minimal risk of drug resistance. But for most
patients, NA therapy remains a long-term therapy, especially in
Hepatitis B e Antigen (HBeAg) negative patients, and there is a
high rate of virologic relapse after cessation of oral therapy.
Due to the long-term therapy, safety of oral drugs is of utmost
importance. Nevertheless, most HBV investigators agree that
NAs are largely safe. No speciﬁc side effects have been associated
with lamivudine and entecavir. Adefovir may damage renal tubu-
lar cells and cause nephrotoxicity [1]. Tenofovir treatment has
been reported to cause some loss in bone mineral density in
patients infected with Human Immunodeﬁciency Virus (HIV)
[2]. In two other recent reports [3,4], Tenofovir in combination
with or without emtricitabine was shown to reveal a small
decrease (mean <2%) in both spine and hip bone mineral density,
although clinically not relevant without increased fracture risk.
Other studies have shown excellent long-term safety with very
low numbers of side-effects [5,6] in mono-infected HBV patients.
Therefore, the induction of renal tubular damage for tenofovir
and its consequences have been regarded as controversial in
HBV mono-infected patients over the last years [7,8]. Induction
of rise of serum creatinine levels greater than 0.5 mg/dl or hypo-
phosphatemia were rare events in the registration trials too.
Finally, an initial report of a higher risk of lactic acidosis for ent-
ecavir-treated patients [9] in a retrospective analysis could not be
conﬁrmed in a prospective trial from the same group of
investigators.Journal of Hepatology 20
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NAs in different stages of clinical development have been pub-
lished. In the ﬁrst study, Yuen et al., [10] report about a two-year
treatment outcome of chronic hepatitis B infection with besifovir,
a new acyclic nucleotide analog, and compared the results to ent-
ecavir treatment. In a roll-over study to 96 weeks from a Phase
IIb open-labelled, multicenter randomized study, the antiviral
efﬁcacy and safety of besifovir 90 mg daily, 150 mg daily, and
entecavir 0.5 mg daily was studied in treatment naïve CHB
patients. Overall, there was no signiﬁcant difference in amount
of HBV-DNA decline, ALT normalization, and loss of HBeAg in
two treatment arms receiving besifovir 90 or 150 mg, compared
to the entecavir 0.5 mg arm. Limitations for this study were a
small sample size after week 48, missing bone density scans
and no quantiﬁcation of HBsAg levels. In respect to safety analy-
sis, there was no difference in SAEs reported, but the most com-
mon side effect related to besifovir was carnitine depletion.
Therefore, carnitine supplementation had to be provided to
84–100% of patients in the besifovir arms. With supplementation,
no patient experienced clinical symptoms of carnitine deﬁciency,
e.g., hypoglycemia, hypoketosis, or even encephalopathy. During
follow-up, carnitine levels normalized again. A potential advan-
tage of besifovir could be a better resistance proﬁle for lamivu-
dine pretreated patients compared to entecavir, but larger scale
studies are required to demonstrate such a theoretical advantage.
In the second study [11], Agarwal et al., report about the
28-day safety, antiviral activity, and pharmacokinetics of tenofo-
vir alafenamide (TAF), a phosphonate prodrug of tenofovir diso-
proxil (tenofovir). Data have been collected in a Phase 1b trial.
The proposal to perform this study was the idea of an improved
safety margin of TAF compared to tenofovir, enabling achieve-
ment of high levels of tenofovir diphosphate within HBV infected
hepatocytes when given at lower doses. The resultant lower sys-
temic exposures of tenofovir are hypothesized to translate into
improved safety margin for TAF. Although early proof of concept
studies had shown greater viral suppression of TAF in vitro
against HIV compared to tenofovir, in this HBV study there was
no difference in antiviral efﬁcacy after 28 days in the TAF and
tenofovir group. There was a higher mean ALT in both TAF groups
compared to the tenofovir arm, with the 40 mg of TAF with a
higher mean ALT compared to 8 mg of TAF. TAF in the 25 mg15 vol. 62 j 505–507
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application appeared to be as safe as tenofovir, while at higher
concentrations of TAF, there was a rising incidence of AEs. No
difference in creatinine clearance, serum phosphate levels or
other markers of bone formation such as bsAP was observed in
TAF versus tenofovir treatment groups.
What do we take home from these two studies? With enteca-
vir and tenofovir, we do have already two NAs of different sub-
classes at hands with extensive real world experience for up to
9 years after licensing for entecavir and up to 7 years for tenofo-
vir. Both drugs are acting as reliable ‘‘working horses’’ in our daily
clinical practice. Treating patients with chronic hepatitis B, >90%
of adherent patients will become HBV-DNA undetectable within
the ﬁrst year of treatment with these drugs, together with nor-
malization of transaminases. Furthermore, there are neglibile
rates of development of drug resistant variants for both com-
pounds, e.g., for entecavir there are only patients at risk that have
been pretreated with lamivudine, for tenofovir there is still after
eight years of reported clinical studies not a single patient with a
conﬁrmed viral resistance so far. Moreover, many different
patient subgroups have been treated in real-life that might be
prone to drug-related safety concerns (e.g., patients of advanced
age, with comorbidities such as diabetes mellitus and arterial
hypertension, suffering from renal insufﬁciency, or with Child
Pugh B cirrhosis). Finally, there is convenient drug dosing with
only one pill per day.
The important remaining aspect of long-term NA therapy is
clearly long-term safety. From the results shown in both studies
here, it appears that we are still far from a proof of concept that
one of those drugs in clinical development, besifovir or tenofovir
alafenamide, might be clinically safer and/or more efﬁcient in the
long-term application compared to entecavir or tenofovir. More-
over, the supplementation of carnitine for besifovir-treated
patients to prevent from carnitine deﬁciency associated symp-
toms, is a clear disadvantage for this drug, not only requiring
another tablet per day in the long-term treatment, but also mak-
ing clinical surveillance in the long-term more complicated and
costly. For TAF, the biggest theoretical advantage might be in
HIV patients on several co-medications, where the majority of
safety signals for tenofovir, kidney and bones, were detected. In
HIV patients, studies with an equivalent TAF drug concentration
are currently in Phase III. Phase II studies in HIV patients detected
a reduced impact on kidney function and BMD [12]. The safety
ﬁndings from on-going trials in HIV patients comparing TAF with
tenofovir might then be of relevance for further HBV develop-
ment, where the 25 mg TAF regimen is currently studied in phase
III clinical trials. For HBV mono-infected patients, the yet theoret-
ical advantage needs to be further clariﬁed with strict observa-
tion of bone scans and kidney function tests, which will require
large scale long-term studies.
Moreover, within the next years, entecavir and tenofovir will
lose their patent protection with the result that these drugs
might be available on a global scale to a more reasonable price
especially in health-care systems that are suffering from budget
restrictions, where, on the other hand, the demand for reliable
drugs against chronic hepatitis B might be the highest. We have
just experienced in the Hepatitis C world that novel drugs
are not coming for penny stocks, so that a safety advantage of
novel drugs needs to be really signiﬁcant to justify probably
higher costs for these drugs in the real world setting.
In summary, is there really an urgent need to search for other
NAs while we are eagerly awaiting the development of novel506 Journal of Hepatology 201anti-HBV drugs with different modes of action against novel tar-
gets in the HBV replication cycle? Is our existing anti-HBV NA
armamentarium not strong enough yet? The development of
novel targets aiming at higher percentages of HBsAg loss, clinical
cure, or even cccDNA silencing in the future should be our main
target in pharmaceutical development. With this, we might be
able to reach a real break-through in getting closer to clinical cure
for our HBV infected patients with a ﬁnite course of treatment.
In the meantime, even combining our two existing forces
against HBV, PegIFN and NAs, in a smarter way to gain more
HBsAg loss to be able to stop antiviral therapy in a larger number
of patients might be of higher clinical relevance. As an example at
The Liver Meeting 2014, the combination of PegIFN and tenofo-
vir led to a signiﬁcant higher rate of HBsAg loss at 72 weeks com-
pared to either mono-therapies and reached the primary
endpoint of that study [13]. It might be worthy to study in greater
detail the possibilities of add-on or switch therapies in this
respect to limit duration of antiviral therapies. Therefore, EASL
considers combination therapy in chronic hepatitis B to be an
area requiring further research and supports further assessment
of the safety and efﬁcacy of the combination of PegIFN with
potent NAs to increase anti-HBe or anti-HBs seroconversion rates
[14]. The two HBV-studies presented in this issue of the Journal of
Hepatology, although clinically very meaningful and important,
will not help us in developing more effective HBV treatments
and long-term safety issues need to be demonstrated with these
drugs before we will put back on the shelf our working horses
entecavir and tenofovir.Conﬂict of interest
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